drugset / Trial / NCT06228391

Ketamine Treatment for PTSD and MDD in TBI

NCT06228391 ↗

Phase 2 Not yet recruiting 40 enrolled Minneapolis Veterans Affairs Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to examine the use of sedative ketamine to treat depression and post-traumatic stress disorder (PTSD) in Veterans with mild to moderate traumatic brain injury (TBI). The main questions it aims to answer are: * Efficacy of ketamine to reduce symptoms of depression and/or PTSD * Safety of ketamine to treat depression and/or PTSD in TBI Participants will be randomly assigned to receive either ketamine or midazolam (active placebo) twice a week for 3 weeks. During participation, subjects will be interviewed, have lab tests, and complete rating scales, and questionnaires.

Timeline

Start
2024-03
Primary completion
2026-12
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous